Go Deep
Avalyn Pharma Inc.
Avalyn Pharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,671 | -9.6 | 2.64 | 0.04 | 2,260.85 |
| Oct 2026 | 19,680 | -9.6 | 2.64 | 0.04 | 2,249.31 |
| Oct 2026 | 19,509 | -10.0 | 2.74 | 0.04 | 2,339.84 |
| Oct 2026 | 19,686 | -9.6 | 2.63 | 0.04 | 2,240.96 |
| Oct 2026 | 19,745 | -9.4 | 2.60 | 0.04 | 2,212.07 |
| Oct 2026 | 19,511 | -10.0 | 2.74 | 0.04 | 2,335.33 |
| Oct 2026 | 19,424 | -10.2 | 2.79 | 0.04 | 2,374.96 |
| Oct 2026 | 19,038 | -11.0 | 3.03 | 0.04 | 2,572.15 |
Avalyn Pharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -28,935,000.0 | -26,869,000.0 | -20,191,000.0 | -17,503,000.0 |
| EPS | -0.7 | -0.6 | -0.5 | -0.4 |
Avalyn Pharma Inc. Revenue & Profit: Last 2 Years
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net Profit | -85,204,000.0 | -49,744,000.0 |
| EPS | -2.0 | -1.2 |
Avalyn Pharma Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Total Assets | 148,881,000.0 | 124,519,000.0 |
| Total Liabilities | 387,537,000.0 | 299,041,000.0 |
| Total Equity | -238,656,000.0 | -174,522,000.0 |
Owes vs Owns
Avalyn Pharma Inc. owed $0.06 for every $1 it owned in Jun 2026, down from $2.40 in Dec 2024.
| Period | Jun 2026 | Dec 2025 | Dec 2024 |
|---|---|---|---|
| Owes vs Owns | 0.06× | 2.60× | 2.40× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Avalyn Pharma Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 92.9%Fixed assets (tangible) 1.6%Other assets 5.1%
How it's funded — Dec 2025
Payables 1.0%Other liabilities 98.6%
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Assets | ||
| Cash & short-term investments | 138.4 | 110.6 |
| Receivables | 0.5 | 0.6 |
| Inventory | 0.0 | 0.0 |
| Fixed assets (tangible) | 2.3 | 0.1 |
| Intangible assets | 0.0 | 0.0 |
| Long-term investments | 0.0 | 7.5 |
| Other assets | 7.7 | 5.7 |
| Liabilities & equity | ||
| Short-term debt | 0.4 | 0.0 |
| Long-term debt | 1.2 | 0.0 |
| Payables | 3.8 | 2.3 |
| Other liabilities | 382.1 | 296.8 |
| Shareholders' equity | -238.7 | -174.5 |
| Net tangible assets | -238.7 | -174.5 |
Avalyn Pharma Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Operating Activities | -81,484,000.0 | -48,368,000.0 |
| Investing Activities | 10,057,000.0 | -91,474,000.0 |
| Financing Activities | 99,787,000.0 | 89,000.0 |